Rate-Control or Rhythm-Control: Where do we stand? by Testa, L et al.
 
www.ipej.org 296
Review Article
Rate-Control or Rhythm-Control: Where do we stand? 
Testa L, Trotta G, Dello Russo A, Casella M, Pelargonio G, Andreotti F, Bellocci F
Institute of Cardiology, Catholic University, Rome, Italy.
Funding or conflict of interest disclosure: none
Address for correspondence: Dr. L. Testa, Institute of Cardiology, Catholic University, Largo F. 
Vito 1 - 00168 Rome, Italy. E-mail: ltes@tiscali.it
Abstract
            Atrial fibrillation is the most common sustained rhythm disturbance and its prevalence is 
increasing worldwide due to the progressive aging of the population. Current guidelines clearly 
depict the gold standard management of acute symptomatic atrial fibrillation but the best-long 
term approach for first or recurrent atrial fibrillation is still debated with regard to quality of life, 
risk of new hospitalizations, and possible disabling complications, such as thromboembolic 
stroke, major bleeds and death. Some authors propose that regaining sinus rhythm in all cases, 
thus re-establishing a physiologic cardiac function not requiring a prolonged antithrombotic 
therapy, avoids the threat of intracranial or extracranial haemorrhages due to Vitamin K 
antagonists or aspirin. On the contrary, advocates of a rate control approach with an accurate 
antithrombotic prophylaxis propose that such a strategy may avoid the risk of cardiovascular and 
non cardiovascular side effects related to antiarrhythmic drugs. This review aims to explore the 
state of our knowledge in order to summarize evidences and issues that need to be furthermore 
clarified.  
Key words: atrial fibrillation, rate control, rhythm control, secondary prevention 
Background
            Atrial fibrillation (AF) is the most common serious rhythm disturbance worldwide1 and 
its incidence progressively increases with the aging of population by two fold with every decade 
after 55 year of age2. It is associated with increased morbidity and mortality3, and it is an 
independent risk factor for stroke: AF increases by 5-fold the overall risk of thromboembolic 
stroke (TES) and by 12-15% in high risk subsets where further risk factors as hypertension, 
diabetes mellitus, heart failure, or previous transient ischemic attack, are present4. A variety of 
symptoms such as reduce exercise tolerance, palpitations, dizziness, dyspnoea or other signs of 
heart failure able to heavily affect the quality of life, may be related to AF5-8. Current guidelines 
clearly state the gold standard approach for symptomatic atrial fibrillation with haemodynamic 
impairment but, on the contrary, whether rate control approach is preferable to rhythm control 
strategy is still debated. 
An Unresolved Dilemma
            Traditionally, a rhythm control approach with electrical or pharmacological cardioversion 
followed by antiarrhythmic drug prophylaxis was preferred by physician even if strong evidence 
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of its superiority have never been available9. Theoretically, restoration and maintenance of sinus 
rhythm holds some advantages as it re-establishes a physiologic cardiac function, avoids the 
unfavourable ventricular and atrial remodelling10,11 due to prolonged tachycardia, and reduce the 
risk of thromboembolic stroke resuming a normal atrial systole. Current guidelines advocate 
anticoagulation for 3-4 weeks before and after cardioversion of AF of >48 hours' duration. 
Alternatively, early cardioversion without anticoagulation may be performed after exclusion of 
left   atrial   thrombi   by   transesophageal   echocardiography1.   Thus,   even   if   evidence   of 
asymptomatic recurrences is growing12, as of now, prolonged anticoagulation is not yet 
recommended after restoration of sinus rhythm, due to the known increased risk of haemorrhagic 
stroke or other major and minor haemorrhages due to Vitamin K antagonists13,14. On the other 
hand, currently available antiarrhythmic drugs have many side effects which in some cases may 
be life threatening as they are proarrhythmic. Amiodarone is the drugs more frequently used in 
published trials but also in clinical practice; noteworthy, some reports stated its relation with 
increased non cardiovascular mortality15-17. Advocates of a simple rate control approach 
associated with an accurate antithrombotic regimen propose that such a strategy would not only 
avoid the proarrhythmic risk of anti arrhythmic drugs but also ensures a better outcome due to 
the beneficial effect of warfarin therapy18. Rate control approach seems to be equally effective in 
improving quality of life (QoL) respect to rhythm control approach even if the major predictor 
of   QoL improvement was sinus rhythm19,20.                                                                                
Rate Control Strategy                                                                                                             
            Generally, a rate control approach is considered effective when associated with relief of 
symptoms and when mean ventricular response ranges between 60 and 80 beats per minute 
(bpm) at rest and between 90 and 115 bpm during a common moderate exercise test1,21. Beta 
blockers, verapamil, diltiazem, digoxin but also amiodarone are effective in reducing the heart 
rate: beta blockers are the drugs of choice in patients with coronary artery disease and, in 
presence of systolic dysfunction, they may be even more valuable22. Verapamil is able to rise the 
serum digoxin levels so the dosage of the latter must be reduced if administered with 
verapamil23. As sole therapy, digoxin may be suitable for elderly patients24. Amiodarone is 
highly effective in controlling the heart rate but many concerns have been raised about its long-
term safety15-17.                                                                                                             
            The “ablate and pace” approach consists of the ablation of atrioventricular node followed 
by implantation of a permanent pacemaker. The ventricular rate is completely controlled by the 
pace-maker and also a more physiological contraction of the ventricle is restored thus positively 
affecting   the   cardiac   haemodynamic25.   As   the   atria   continue   to   fibrillate,   the   need   of  
anticoagulant therapy remains unchanged. In patients with heart failure and refractory to other 
treatment, this approach was found to be associated with better control of palpitations, 
improvements of dyspnoea and quality of life26. No improvement of cardiac performance26 
neither   prolonged   survival27  were   observe   with   “ablate   and   pace”   strategy   respect   to 
pharmacological therapy. In some cases a modulation instead of ablation of atrioventricular node 
may be efficacious to improve symptoms28.                                                 
Rhythm   Control  Strategy                                                                                 
            Current guidelines state which antiarrhythmic drugs have proven efficacy in converting 
atrial fibrillation into sinus rhythm both for atrial fibrillation with less and more than 7 days of 
duration1. Also which drugs are effective in increasing the success rate of electrical cardioversion 
are   described1.   All   of   these   antiarrhythmic   drugs   are   burdened   by   the   risk   of   serious 
cardiovascular   and   non   cardiovascular   side  effects,   including  life  threatening  ventricular 
arrhythmias (all), lupus like syndrome (procainamide), heart failure (disopyramide, propafenone, 
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flecainide, sotalol), pulmonary toxicity (amiodarone, sotalol). A recent meta analysis supports 
the efficacy of amiodarone in converting persistent atrial fibrillation29 but its known thyroid, 
hepatic, and pulmonary toxicity should make it a second line agent30.                           
            Electrical cardioversion has a very high initial success rate, but only about 23% of 
patients at 1 year and 15% at 2 years remain in sinus rhythm31,32. Many studies investigated the 
clinical and instrumental factors able to predict the risk of relapse; the most common accepted 
are: AF duration more than 1 year, age > 75 year, heart failure and increased atrial dimension33.  
Currently, for patients with unknown atrial fibrillation duration or more than 48 hours, 
cardioversion is recommended after a 3 weeks period of anticoagulation and it has to be followed 
by a month of anticoagulation1. A transoesophageal echocardiography-guided approach showed 
a similar risk of stroke compared to conventional management34 thus suggesting that the risk of 
stroke is not completely abolished restoring sinus rhythm, even if transoesphageal examination is 
negative for intra atrial clot.                                                                                                                 
              Recently, newer strategies were developed, including catheter ablation by means of 
radiofrequency. Ectopic foci, localized within the pulmonary vein, were found in the majority of 
atrial fibrillation35  and the ablation of this triggers, despite a little but predictable risk of 
iatrogenic morbidity36, seems to be very promising in light of a chance of “real” cure for atrial 
fibrillation37. Device-based  therapy38 but also surgical treatment with the Cox-Maze procedure 
have been developed in the last years with some promising results39.                                       
Randomized Trials of Rate vs Rhythm                                                                                     
 
            Several trials addressing this issue were published in the last years40-45 and 2 other are 
still ongoing46,47. The Pharmacological Intervention in Atrial fibrillation (PIAF)40 enrolled 252 
patients with persistent atrial fibrillation duration up to 360 days. In the first arm the strategy 
was  to control heart rate using diltiazem while, in the second, restoration and maintainance of 
synus rhythm was obtained using amiodarone or electrical cardioversion as first intervention 
followed by various antiarrhythmic drugs.  Follow up length was 1 year. The primary end point 
of   the   study   was   improvement   in   symptoms   related   to   atrial   fibrillation.
     The Strategies of Treatment of Atrial Fibrillation  study (STAF)41 enrolled 200 patients with 
persistent atrial fibrillation. In the rhythm control arm patients were to be cardioverted by 
external or internal cardioversion; after restoration of sinus rhythm, prophylaxis was performed 
with class I antiarrhythmic drugs or sotalol, in the absence of coronary artery disease (CAD) and 
in the presence of normal left ventricular ejection fraction, while in the presence of impaired 
ventricular function or CAD, beta-blockers or amiodarone were used.  In the rate control arm 
beta-blockers, digitalis, calcium antagonists, or atrioventricular node ablation/modification with 
or without pace maker implantation were used. Follow up was of 19.6 + 8.9 months. Primary end 
point was the combined rate of death, cardiopulmonary resuscitation, cerebrovascular events and 
systemic   embolism.                                                                  
The RACE study42 enrolled 522 patients with persistent atrial fibrillation after an initial attempt 
of electrical cardioversion. Rate control was achieved with administration of digitalis, calcium 
antagonists, and beta-blockers alone or in combination. Rhythm control was obtained with 
electrical cardioversion without previous treatment with antiarrhythmic drugs. Thereafter, sotalol 
was used for prophylaxis. At the first recurrence of atrial fibrillation, electrical cardioversion was 
repeated and sotalol replaced by flecainide. In the presence of a recurrence within 6 months 
another cardioversion was performed and flecainide replaced by amiodarone. Follow up length 
was 2.3 + 0.6 years. The primary end point was a composite of cardiovascular death, heart 
failure, thromboembolic complications, bleeding, implantation of a pace-maker, and severe 
adverse effects of drugs.                                                                                               
            The AFFIRM study43 enrolled 4060 patients with first or recurrent atrial fibrillation at 
high risk for stroke in a randomized, multicenter comparison. Risk  factors for  stroke  were 
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considered hypertension, diabetes mellitus, congestive heart failure, prior transient ischemic 
attack, cerebrovascular accident, systemic embolism history, left atrial size of 50mm or more, 
LVEF less than 40%. Digitalis, calcium antagonists, and beta-blockers alone or in combination 
were the drugs accepted in the rate control arm: the goal was a heart rate not higher than 80 beats 
per minute at rest and 110 beats per minute during six minute walk test. In the rhythm control 
arm the antiarrhythmic drug was chosen by the treating physician: attempts to maintain rhythm 
control   could   include   cardioversion.   The   following   drugs   were   acceptable:   amiodarone, 
disopyramide, flecainide, moricizine, procainamide, propafenone, quinidine, sotalol, and their 
combination according to an imposed protocol. Mean follow up length was 3.5 years.   The 
primary end point was overall mortality but several other clinical end-points were reported. 
            The HOT CAFÉ44 enrolled 205 patients with a mean time of atrial fibrillation duration of 
273 ± 112.4 days. In the rate control arm beta blockers, calcium antagonists, digoxin alone or in 
combination were the pharmacological treatment. Patients randomised to rhythm control strategy 
were all treated with electrical cardioversion and subsequent antiarrythmic drugs. Follow up 
length was 1.7 ± 0.4 years. Primary end point was a composite of death from any cause, 
thromboembolic complications (especially disabling stroke), and intracranial or other major 
haemorrhage.  
            The Control of Rate versus Rhythm in Rheumatic Atrial Fibrillation trial (CRRAFT)45 
trial differs from the others because it enrolled patients with rheumatic heart disease and chronic 
atrial fibrillation. Forty-eight patients randomized to rate control received 90 mg sustained 
release diltiazem twice daily to maintain the resting ventricular rate below 90 beats/min, and less 
than 130 beats/min with activity. No attempt to restore SR with drug therapy or electroversion 
was made. Those who entered the rhythm control group were further randomized in a double-
blind design to receive either amiodarone or placebo and electrical conversion, wherever 
required. Follow up length was 1 year. Primary end points were: exercise tolerance assessed by 
Bruce protocol treadmill exercise, NYHA class, QOL score, thromboembolic and bleeding 
complications, hospitalization rates, and deaths. While the CRRAFT trial suggested that 
maintenance of sinus rhythm appeared to be superior to ventricular rate control in patients with 
rheumatic atrial fibrillation in terms of an effect on mortality and morbidity, none of the single 
published trials on non-rheumatic atrial fibrillation shows statistically significant difference 
between the two strategies, only suggesting a possible superiority of rate control approach in 
terms of a trend toward a reduced risk of major adverse cardiovascular events. On the other hand, 
a recent meta-analysis of our groups48 stated the superiority of rate control strategy, in patient 
with non rheumatic atrial fibrillation,  in reducing the risk of the combined end point of all cause 
death and thromboembolic stroke without any increase in the risk of major haemorrhages. This 
superiority seems even more evident by the low number needed to treat to avoid one combined 
end point as it results equal to 50. Rate control strategy confirmed its superiority in reducing the 
combined end point compared to the rhythm control approach  even when older patient or longer 
follow up were considered. Notably, the risk of thromboembolic stroke is strongly reduced  in 
the early period after the beginning of therapy as demonstrated in the studies with mean follow 
up < 20 months in which we observed a reduction of 82%.                                     
Conclusions
            In the evidence-based medicine era the highest level of evidence is that of meta-analytic 
approach49 but the results presented above should be cautiously viewed as hypothesis generating 
not as the definitive answer, for some reasons: 1) the results do not apply to all subsets of 
patients with atrial fibrillation because patients with Wolff-Parkinson-White syndrome, those 
who had previously undergone heart surgery, or those with  NYHA class IV heart failure were 
excluded by the trials’ designs; 2) all published studies had at least a small percentage of patients 
crossing over the randomization arms but the statistical analyses were performed by intention to 
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treat thus underestimating this effect, and 3) even if amiodarone was the antiarrhythmic drug 
more frequently used, other agents have been adopted, anyone with its own risk/benefit profile, 
thus   generating   another   confounding   factor   to   take   into   account.  
            In a post hoc analysis of AFFIRM population the trend toward a lower total mortality in 
the   rate-control   versus   the   rhythm-control   group   appears   entirely   explained   by   non 
cardiovascular deaths. Independent predictors of non cardiovascular death were rhythm-control 
strategy, age, male gender, previous smoking history, heart failure, and coronary heart disease50. 
In another analysis, the authors stated that digoxin and antiarrhythmic drugs were directly 
associated, while the presence of sinus rhythm and warfarin therapy were inversely associated 
with increased mortality after adjustment for other covariates51. The meaning of these separate 
observations may be that pursuing sinus rhythm may improve prognosis, but this potential 
advantage has to be weighted against various non cardiovascular adverse effects of the agents 
used to obtain and maintain it.                                                                               
            As previously stated, current guidelines recommend only a short term anticoagulation 
therapy after restoration of sinus rhythm while those patients treated with rate control approach 
continue to take Vitamin K antagonists or aspirin potentially for all the life. This issue rises some 
concerns: oral anticoagulants, but also aspirin, are associated with at least a two fold risk of 
major haemorrhages compared to placebo13, on the other hand, current available antiarrhythmic 
drug are burdened by a substantial risk of ventricular arrhythmias. A patients treated with rhythm 
control approach have not an increased risk of haemorragies but an increased risk of sudden 
death. The contrary may be told for those treated with rate control strategy. In these patients with 
atrial fibrillation, with so many different clinical features, what is the highest and worst risk? An 
haemorrhagic stroke or a malignant arrhythmia? We have not enough evidence to answer this 
pivotal   question.
            As previously reported48, there is an early large excess of thromboembolic stroke in 
patients randomized to a rhythm-control strategy possibly because the risk of stroke associated 
with electrical cardioversion is not entirely abolished by short term anticoagulation. Moreover,  
symptomatic   or   asymptomatic   recurrences   are   frequent12  thus   increasing   the   risk   of 
thromboembolic stroke in patients possibly taking neither aspirin nor Vitamin K antagonists. 
            In the future, new, safer and more effective antiarrhythmic agents, associated with careful 
and prolonged anticoagulation, will probably make the rhythm-control strategy superior to the 
rate control one but, according to current evidence, rate-control strategy represents the gold 
standard strategy, especially for those patients with echocardiographic and clinical features that 
make unlikely the maintenance of sinus rhythm with or without antiarrhythmic prophylaxis for 
recurrences. 
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